Department of Senior Healthcare, BK21 Plus Program, Graduate School, Eulji University, Daejeon 34824, Republic of Korea.
Department of Biomedical Laboratory Science, School of Medicine, Eulji University, Daejeon 34824, Republic of Korea.
Mol Med Rep. 2019 Sep;20(3):2476-2483. doi: 10.3892/mmr.2019.10454. Epub 2019 Jul 1.
Atopic dermatitis (AD) is an inflammatory skin disorder caused by immunological dysregulation and genetic factors. Whether the expression levels of cytokine and skin barrier protein were altered by S100 calcium binding protein A8 (S100A8) and S100A9 in human keratinocytic HaCaT cells was examined in the present study. Alterations of cytokine expression were examined by ELISA following treatment with S100A8/9 and various signal protein‑specific inhibitors. Activation of the mitogen activated protein kinase (MAPK) pathway and nuclear factor (NF)‑κB was evaluated by using western blotting and an NF‑κB activity test, respectively. The expression levels of interleukin (IL)‑6, IL‑8 and monocyte chemoattractant protein‑1 increased following treatment with S100A8 and S100A9, and the increase was significantly blocked by specific signaling pathway inhibitors, including toll‑like receptor 4 inhibitor (TLR4i), rottlerin, PD98059, SB203580 and BAY‑11‑7085. Extracellular signal‑regulated kinase (ERK) and p38 MAPK pathways were activated in a time‑dependent manner following treatment with S100A8 and S100A9. Phosphorylation of ERK and p38 MAPK were blocked by TLR4i and rottlerin. S100A8 and S100A9 induced translocation of NF‑κB in a time‑dependent manner, and the activation of NF‑κB was inhibited by TLR4i, rottlerin, PD98059 and SB203580. In addition, S100A8 and S100A9 decreased the expression of skin barrier proteins, filaggrin and loricrin. These results may help to elucidate the pathogenic mechanisms of AD and develop clinical strategies for controlling AD.
特应性皮炎(AD)是一种由免疫失调和遗传因素引起的炎症性皮肤病。本研究旨在探讨 S100 钙结合蛋白 A8(S100A8)和 S100A9 是否改变人角质形成细胞 HaCaT 细胞中细胞因子和皮肤屏障蛋白的表达水平。用 ELISA 检测 S100A8/9 及各种信号蛋白特异性抑制剂处理后细胞因子表达的变化。用 Western blot 法和 NF-κB 活性测定法分别评价丝裂原活化蛋白激酶(MAPK)途径和核因子(NF)-κB 的激活。S100A8 和 S100A9 处理后,白细胞介素(IL)-6、IL-8 和单核细胞趋化蛋白-1 的表达水平增加,TLR4 抑制剂(TLR4i)、rottlerin、PD98059、SB203580 和 BAY-11-7085 等特异性信号通路抑制剂可显著阻断该增加。S100A8 和 S100A9 处理后,细胞外信号调节激酶(ERK)和 p38 MAPK 途径呈时间依赖性激活。TLR4i 和 rottlerin 可阻断 ERK 和 p38 MAPK 的磷酸化。S100A8 和 S100A9 可诱导 NF-κB 呈时间依赖性转位,TLR4i、rottlerin、PD98059 和 SB203580 可抑制 NF-κB 的激活。此外,S100A8 和 S100A9 降低了皮肤屏障蛋白丝聚蛋白和兜甲蛋白的表达。这些结果可能有助于阐明 AD 的发病机制,并为控制 AD 开发临床策略。